- Home
- TSI vs GOSS Comparison
TSI vs GOSS Comparison
Compare TSI & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- GOSS
- Stock Information
- Founded
- TSI 1987
- GOSS 2015
- Country
- TSI United States
- GOSS United States
- Employees
- TSI N/A
- GOSS N/A
- Industry
- TSI Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- GOSS Health Care
- Exchange
- TSI Nasdaq
- GOSS Nasdaq
- Market Cap
- TSI 244.7M
- GOSS 246.6M
- IPO Year
- TSI N/A
- GOSS 2019
- Fundamental
- Price
- TSI $5.05
- GOSS $1.02
- Analyst Decision
- TSI
- GOSS Strong Buy
- Analyst Count
- TSI 0
- GOSS 5
- Target Price
- TSI N/A
- GOSS $9.20
- AVG Volume (30 Days)
- TSI 106.8K
- GOSS 962.5K
- Earning Date
- TSI 01-01-0001
- GOSS 11-07-2024
- Dividend Yield
- TSI 7.46%
- GOSS N/A
- EPS Growth
- TSI N/A
- GOSS N/A
- EPS
- TSI N/A
- GOSS N/A
- Revenue
- TSI N/A
- GOSS $95,842,000.00
- Revenue This Year
- TSI N/A
- GOSS N/A
- Revenue Next Year
- TSI N/A
- GOSS N/A
- P/E Ratio
- TSI N/A
- GOSS N/A
- Revenue Growth
- TSI N/A
- GOSS N/A
- 52 Week Low
- TSI $4.48
- GOSS $0.45
- 52 Week High
- TSI $4.87
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- TSI 34.97
- GOSS 54.87
- Support Level
- TSI $5.05
- GOSS $1.01
- Resistance Level
- TSI $5.10
- GOSS $1.09
- Average True Range (ATR)
- TSI 0.06
- GOSS 0.07
- MACD
- TSI -0.02
- GOSS 0.00
- Stochastic Oscillator
- TSI 0.00
- GOSS 46.02
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.